Saudi Pharmaceutical Journal 27 2019 491501 Contents lists available ScienceDirect Saudi Pharmaceutical Journal j o u r n l h o m e p g e w w w s c e n c e d r e c t c o m Original article Nanoencapsulation characterization baricitinib polylactic glycolic acid copolymer Mohammad Javed Ansari Saad M Alshahrani Department Pharmaceutics College Pharmacy Prince Sattam Bin Abdulaziz University Alkharj Saudi Arabia r t c l e n f o b s t r c t Article history Received 15 November 2018 Accepted 10 January 2019 Available online 12 January 2019 Keywords Baricitinib Nanoparticles Nanoprecipitation Encapsulation Solubility Dissolution 1 Introduction Baricitinib recently approved antirheumatic drug having poor aqueous solubility performance suffers low inconsistent oral bioavailability The purpose study develop evaluate poly lacticcoglycolic acid PLGA nanoparticles baricitinib order enhance vitro dissolution performance Nanosuspension baricitinib PLGA biodegrad able FDA approved semisynthetic polymer developed nanoprecipitation method Research methodology employed quantitative research utilizing experimental design effect indepen dent variables polymer drug polymer ratio types solvent solvent antisolvent ratio evaluated size size distribution nanoparticles entrapment efﬁcien cies Among organic phases evaluated acetone suitable solvent drug polymer The aqueous phase antisolvent deionized water containing 1 wv pluronic 127 stabilizer nanoparticle suspension The optimized nanoparticles particle size 100 nm 91 nm 623 narrow size distribution 0169 0003 high zeta potential cid1125 mV 546 entrapment efﬁciency 880 The optimized nanoparticles characterized scanning electron microscopy Xray diffraction differential scanning calorimetry infrared spec troscopy vitro dissolution studies Invitro dissolution study PLGA nanoparticles exhibited sus tained release approximately 93 release baricitinib 24h period cid1 2019 The Authors Production hosting Elsevier BV behalf King Saud University This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 Rheumatoid arthritis autoimmune disorder causes inﬂammation joints knees ankles hands feet leads swelling pain immobility Aletaha et al 2010 Treat ment options available treat disease include nonsteroidal antiinﬂammatory disease NSAID modifying antirheumatic drugs DMARD injectable biologics Baricitinib new subclass DMARD recently approved oral immediate release tablets USFDA treatment rheumatoid arthritis especially patients responding available therapies Drug Approval Package Olumiant baricitinib 2018 It selective inhibitor Janus kinase 1 corticosteroids drugs Corresponding author Email addresses mjansaripsauedusa MJ Ansari smshahranipsauedusa SM Alshahrani Peer review responsibility King Saud University Production hosting Elsevier 2 JAK 1 JAK 2 Janus kinases group enzymes acti vate signal transducers activators transcription enabling inﬂammation immune function Assessment report Olumiant 2018 Baricitinib aromatic polyheterocyclic compound Fig 1a molecular formula molecular weight C16H17 N7O2S 37142 respectively Assessment report Olumiant 2018 As assessment report baricitinib belongs class III biopharmaceutical classiﬁcation BCS means highly soluble poorly permeable drug report mentioned baricitinib practically insoluble Assessment report Olumiant 2018 Nevertheless reported solubility 0357 mgml water permeability Log P 108 challenges drugbank identiﬁ cation report Drugbank identiﬁcation baricitinib 2018 Baric itinib reported soluble organic solvents dimethyl sulphoxide 74 mgml dimethyl formamide 50 mg ml poorly soluble water ethanol 1 mgml 25 cid3C Baricitinib technical information 2018 Another product information baricitinib reported poor aqueous solubility baricitinib cid305 mgml 11 mixture phosphate buffer saline pH 72 dimethyl formamide solubility organic solvents like dimethyl sulphoxide dimethyl formamide httpsdoiorg101016jjsps201901012 13190164cid1 2019 The Authors Production hosting Elsevier BV behalf King Saud University This open access article CC BYNCND license httpcreativecommonsorglicensesbyncnd40 492 MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 purchased SigmaAldrich St Louis MO Acetone AC acetonitrile AN dichloromethane DCM ethylacetate EA tetrahydrofuran THF analytical grade pur chased SigmaAldrich St Louis MO Deionized water obtained MilliQ Millipore Massachusetts USA 22 Methods The research methodology employed quantitative research utilizing experimental design effect dependent vari ables nanoparticle size size distribution polydispersity indexPDI zeta potential entrapment efﬁciency inde pendent variables polymer drug type sol vent solvent antisolvent ratio investigated 23 Formulation baricitinib encapsulated nanoparticles Fig 1 Molecular structures baricitinib b Poly lacticcoglycolic acid n number units lactic acid m number units glycolic acid cid350 mgml Product information baricitinib 2018 Drugs poor solubility permeability suffer low inconsistent bioavailability affecting performance therapeutic goals Dahan Miller 2012 Moreover low bioavailability necessi tates administration higher doses lead effects Oral bioavailability aqueous solution baricitinib 05 methylcellulose reported 48 dogs 54 rats 4768 monkey 79 human Assessment report Olumiant 2018 Pharmacokinetic parameters Cmax Tmax AUC01 total clearance elimination halflife oral admin istration baricitinib healthy volunteer reported cid3112 nM cid31h 740 nM cid4 h cid317 Lh cid38 h respectively Assessment report Olumiant 2018 The intersubject variability pharmacokinetic parameters reported moderate range 17 26 healthy volunteers patients rheumatoid arthritis high 41 Assessment report Olumiant 2018 There techniques improve solubility bioavail ability drugs Polymeric nanoparticles based PLGA Fig 1b investigated extensively enhancement solubility bioavailability poorly soluble drugs certain advantages biodegradable biocompatible nature copolymer Moreover nonimmunogenic nontoxic approved FDA biomedical pharmaceutical appli cations Makadia Siegel 2011 The recent literature search revealed PLGA widely polymeric mate rials employed fabrication nanoparticles It reported enhance solubility bioavailability poorly soluble drugs resveratrol Singh Pai 2014 nelﬁnavir Venkatesh et al 2015 lopinavir Joshi et al 2016 docetaxel Raﬁei Haddadi 2017 benzophenone Costabile et al 2018 This study undertaken develop evaluate baric itinib encapsulated PLGA nanoparticles improve dissolution performance drug There report investigation solubility bioavailability baricitinib encapsulated PLGA nanoparticles 2 Materials methods 21 Materials Baricitinib purchased Mesochem Technology Co Ltd Beijing China PLGA polymer 5050 Pluronic acid 127 Baricitinib encapsulated PLGA nanoparticles prepared nanoprecipitation method involves precipitation insol uble drugs aqueous phase organic solution drug polymer mixture added slowly aqueous phase kept moderate stirring Fessi et al 1989 Deﬁnite baricitinib PLGA dissolved suitable organic solvent added dropwise antisolvent kept moderate stirring 700 rpm The mixture stirred night remove rendered hardening nanoparticles organic Nanosuspension centrifuged 15000 cid4 rcf Centurion scien tiﬁc UK 30 min separate nanoparticles washed cold water freeze dried Mill rock technology Kingston NY analyses solvent 231 Effect solvent Various organic solvents like acetone AC acetonitrile AN dichloromethane DCM ethyl acetate EA tetrahydrofuran THF investigated optimize organic phase nano precipitation Accurately weighed PLGA 50 mg baricitinib 10 mg dissolved separately 10 ml organic solvent prepare different formulation formulation codes F1F5 presented Table 1 The prepared organic phases added dropwise 50 ml antisolvent 1 aqueous pluronic 127 kept magnetic stirrer rotating 700 RPM 232 Effect antisolvent To investigate effect antisolvent nanoprecipitation different ratio solvent antisolvent 12 13 15 110 investigated optimization nanoparticles Accurately weighed baricitinib 10 mg PLGA 50 mg dissolved 10 ml acetone solvent drug polymer The deionized water antisolvent containing 1 pluronic 127 stabilizer The composition formulations F6F9 presented Table 2 233 Effect polymer To investigate effect polymer formulation charac teristics polymer concentration varied range Table 1 Formulation codes composition nanoparticles containing 10 mg baricitinib 50 mg PLGA Formulation number Organic solvent Formulation code F1 F2 F3 F4 F5 Acetone Acetonitrile Dichloromethane Ethyl acetate Tetra hydro furan AC AN DCM EA THF MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 493 Table 2 Formulation codes composition nanoparticles containing 10 mg baricitinib 50 mg PLGA prepared varying solvent antisolvent ratio Formulation number Formulation code Solvent ml Antisolvent ml F6 F7 F8 F9 SAS12 SAS13 SAS15 SAS110 10 10 10 10 20 30 50 100 1 10 mgml acetone The organic phase containing 10 mg baricitinib different PLGA range 110 mgml prepared 10 ml acetone different formulations F10F13 presented Table 3 The prepared organic phases added dropwise 50 ml anti solvent 1 aqueous pluronic 127 kept magnetic stirrer rotat ing 700 RPM 234 Effect drug The effect drug particle size size distribution zeta potential investigated preparing formulations drug polymer The composition formulations F14F16 presented Table 4 The component s dis solved 10 ml acetone prepare organic phases F 16 prepared suspending 10 mg baricitinib 1 pluronic 127 comparison purpose The prepared organic phases added dropwise 50 ml antisolvent 1 aque ous pluronic 127 kept magnetic stirrer set 700 RPM 24 Optimization nanoparticles The prepared nanoparticle formulations optimized basis visual appearance agglomeration particle size size dis tribution polydispersity index zeta potential entrapment efﬁciency 241 Particle size size distribution The particle size size distribution investigated dynamic light scattering DLS technique ﬂuctualtions intensity scattered light measured function movement diffusion nanoparticles The smaller nanoparti cles faster diffusion Brownian motion described Eq 1 derived StokeEinstein diffusion equation Eq 2 Faster diffusion nanoparticles result rapid ﬂuctualtions scattered light These ﬂuctuations scattered light measured photon counter corre lated diffusion coefﬁcient nanoparticle hydrodynamic Table 3 Formulation codes composition nanoparticles containing 10 mg baricitinib varying amounts PLGA dissolved 10 ml acetone Formulation number Formulation code polymer concentration mgml polymer mg F10 F11 F12 F13 PLGA 1 PLGA 2 PLGA 3 PLGA 10 1 2 3 10 10 20 30 100 Table 4 Formulation codes composition nanoparticles baricitinib PLGA dissolved 10 ml acetone Formulation number Formulation code Baricitinib mg PLGA mg F14 F15 F16 DP10 DP0 1 D P10 10 0 10 0 10 0 F16 prepared suspending drug 1 pluronic 127 size nanoparticle DLS technique called pho ton correlation spectroscopy PCS In study employed state art equipment Zetasizer Nano ZS model ZEN3500 Malvern Instruments UK particle size size distribution measurement It utilizes patented noninvasive scatter NIBS technology measures scattered light backscat ter angle 173cid3 improving sensitivity measuring capacity The nanoparticles cid35 mg suspended 10 ml deionized water vortex mixing 30 s followed ultrasonication 60 s break agglomerates Appropriate volume approxi mately 2 ml prepared nanoparticle suspension taken disposable plastic cuvette Particle size measured triplicate 25 cid3C The size nanopartilces reported Z average diameter Eq 3 intensity based harmonic mean diameter calculated cumulant analysis squares ﬁt ting considered relatively insensitive experimental noise Finsy De Jaeger 1991 R ¼ kBT 6pgD R Hydrodynamic radius nanoparticle kB Boltzmans constant T Temperature g Viscosity dispersion medium D Diffusion coefﬁcient D ¼ kBT 6pgR P SiP Dz ¼ ðSiDiÞ ð1Þ ð2Þ ð3Þ Dz Z average diameter Si Scattered intensity nanoparticle Di Diameter nanoparticle 242 Evaluation zeta potential nanoparticle suspension The zeta potential disperse systems nanoemulsions nanosuspensions important characteristics helps stability dispersions It potential difference phase boundaries dispersed phase disper sion medium It considered index repulsion higher zeta potential higher repulsion dispersed particles similar charges resulting stable dispersions The magnitude zeta potential mainly depends charges dispersed phase dispersion medium turn inﬂuenced dielectric constantionic strength conductiv ity viscosity pH dispersion medium described Henry equation Eq 4 Therefore evaluation zeta potential nanoparticle suspension important predict fate stability transportation absorption bodybody tissues Zeta potential nanoparticles determined experimentally measuring electrophoretic mobility nanoparticles measurement velocity nanoparticles moving electrodes electrical ﬁelds The higher velocity higher magnitude zeta potential In study zetasizer nano ZS Malvern Instrument UK patented mixed mode measurement phase analysis light scattering M3 PALS capable measuring mean zeta potential zeta potential distribution excellent accuracy Brieﬂy nanoparticles cid35 mg suspended 10 ml 10 mM sodium chloride vortex mixing 30 s followed ultrasonication 494 MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 60 s break agglomerates The appropriate volume cid309 ml nanosuspension introduced help syringe specialized polycarbonate zeta cells folded capillary cell goldplated electrodes model DTS1017 Malvern Instruments held inverted position avoid introduction air bubbles Caps zeta cells close cell Zeta potential measured triplicate 25 cid3C le ¼ 2zef ðkaÞ ð4Þ 3g le electrophoretic mobility z zeta potential e dielectric constant fk Henrys function equals 15 polar dispersant known Smoluchowski approximation g viscosity dispersion medium 243 Drug entrapment efﬁciency nanoparticles The drug entrapment efﬁciency nanoparticle formulations calculated indirect method involded sedimentation nanoparticles ultracentrifugation followed analysis unentrapped drug supernetant The difference drug added initially formulation unentrapped drug supernetant gives drug entrapped formulation Brieﬂy nanoparticle suspensions centrifuged 15000 cid4 rcf 30 min The supernetant obtained analyzed bouble beam UV spectrophotometer UV 630 Jasco Japan 224 nm appropriate dilution The entrapment efﬁciency formulation calculated mentioned Eq 5 Entrapment ¼ Drug loaded cid1 Drug X100 ð5Þ Drug loaded The drug loading capacity calculated direct method involved comparison practically loaded drug analysis nanoparticle solution theoretical drug taken beginning load polymer Eq 6 Brieﬂy 10 mg dried nanoparticles dissolved acetone diluted appropriately analyzed double beam UV spectrophotometer UV 630 Jasco Japan 224 nm Drug loading ¼ Amount drug Amount drug polymer X100 ð6Þ 25 Characterization baricitinib encapsulated PLGA nanoparticles The characterization optimized nanoparticle carried studying size surface morphology Scanning Electron Microscopy SEM powder properties Xray Diffractrometry XRD Differential Scanning Calorimetry DSC Fourier Transform Infra Red spectroscopy FTIR vitro drug release studies release mechanism 251 Size surface characterization The size surface baricitinib encapsulated nanoparticles characterized Scanning Electron Microscopy Zeiss EVO LS10 Cambridge UK The dried nanopartilces suspended ml deionized water sonicated 1 min break agglomeration A drop nanoparticle suspension ﬁxed carbon tape SPI Supplies West Chester PA gold coated vacuum Q150R sputter coater Quorum Technolo gies Ltd East Sussex UK argon atmosphere 20 mA 60 s Alshehri et al 2017 252 Xray diffractometry XRD nanoparticles The Xray diffractometry pure baricitinib baricitinib encapsulated PLGA nanopartilces conducted compare powder characteristics nanoencapsulation Altima IV Xray diffractometer Rigaku Japan The appropriate dried nanopartilces pure drug samples placed XRD sample holder pressed help glass slide The X ray diffraction patterns 2h obtained scanning samples 5cid3 60cid3 step size step time 002cid3 05 s respectively Ansari 2016 253 Differential scanning calorimetry DSC The differential scanning calorimetry drug drug encapsulated nanoparticles carried DSCN 650 SCINCO Italy Approximately 5 mg pure drug sample drug encapsulated nanoparticles crimped aluminum pans Empty aluminum pan crimped similarly reference material The sample reference p laced sample holder scanned 50 250 cid3C rate 10 cid3C minute nitrogen gas ﬂowing 20 ml minute 254 Fourier transform infrared spectroscopy FTIR Fourier transform infrared spectroscopy drug drug enclosed nanoparticles conducted potassium bro mide KBr disc technique FTIR instrument FTIR4600 Jasco Japan Approximately 5 mg drug drug encapsulated nanoparticles mixed triturated equal KBr mortar The obtained mixtures compressed Quick Press KBr pellet kit obtain ﬁlms The sample ﬁlm mounted sample holder scanned wavenumber range 4004000 cmcid11 taking background scan 255 In vitro release study In vitro release study nanoparticles performed sample separate method Shen Burgess 2013 The nanoparticle sample containing cid310 mg drug weighed introduced 25 ml release media phosphate buffer pH 68 containing 05 wv Sodium lauryl sulphate kept thermostated 37 1 cid3C biological shaker rotating 100 RPM LBS030SLab Tech Korea An aliquot 1 ml sampled 0 05 1 2 4 8 12 24 h addition nanoparticles release media Fresh media introduced sampling maintain sink condition Withdrawn samples centrifuged 15000 rcf 30 min analyzed double beam UV spectrophotometrically 224 nm The release kinetics mechanism drug release nanoparticles studied ﬁtting release data zero order ﬁrst order Higuchi KorsmeyerPeppas plots Mu Feng 2003 The release rate constants k n models calculated lin ear regression analysis 3 Results discussions 31 Formulation baricitinib encapsulated PLGA nanoparticles It simplest methods Fabrication baricitinib encapsulated PLGA nanoparticles achieved nanoprecipitation method Fessi et al 1989 fabrication nanopartilces based technology It involved solu bilization baricitinb PLGA suitable organic solvent followed slow addition prepared organic phase aqueous phase resulting nanoprecipitation We prepared sev eral formulations investigated effect indepen dent variables PLGA baricitinib PLGA ratio nature organic solvent solvent antisolvent ratio fabrication nanoparticles MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 495 32 Optimization baricitinib encapsulated nanoparticles The development optimization nanoparticles formed investigating effect independent variables polymer drug types solvent antisolvent varying ratio dependent variable size size distribution zeta potential entrapment efﬁciency nanoparticle suspension 321 Effect solvent Several solvents investigated select optimum sol vent nanoprecipitation based absence agglomeration parameters nanoparticle size size distribution zeta potential entrapment efﬁciency Formulation 1 F1 containing acetone optimized selected solvent polymer lowest size drug based absence agglomeration 120 nm smallest PDI 0091 highest zeta potential cid185 mv good entrapment efﬁciency Fig 2 The entrapment efﬁ ciency formulation acetonitrile F2 dichloromethane F 3 higher 932 919 respectively However formulations chosen optimum owing larger nanoparticle size PDI 964 nm 0804 608 nm 0643 F2 F3 respectively The effect solvent size size dis tribution entrapment efﬁciency nanoparticles understood Smaller sizes nanoparticles formulation F1 ascribed better solubility PLGA acetone better diffusion acetone antisolvent compared solvents Moreover low boiling point high dielectric constant high water miscibility acetone advantageous producing smaller size nanoparticles Huang Zhang 2018 322 Effect antisolvent Various ratio solvent antisolvent 12 13 15 110 tested optimization nanoparticles based size PDI zeta potential entrapment efﬁciency Decrease sol ventantisolvent ratio 12 15 resulted reduction par ticle size PDI cost loss entrapment efﬁciency Further decrease phase ratio resulted larger nanoparticles higher entrapment efﬁciency A solvent anti solvent ratio 15 formulation number F8 chosen optimum formulation based smallest size 91 nm lowest PDI 0169 highest zeta potential value cid1125 entrapment efﬁciency 880 Fig 3 The smaller sizes nanoparticles smaller solventantisolvent ratio attribu ted low viscosity mixture better diffusion solvent antisolvent Sahu Das 2014 323 Effect concentration PLGA nanoparticles Organic solutions PLGA concentration investigated optimization nanoparticles based size PDI zeta potential entrapment efﬁciency Increasing concen tration polymer organic solution resulted increase size entrapment efﬁciency nanoparticles Fig 4 Formula tion F10 contains lowest concentration PLGA 1 mg ml acetone resulted smallest nanoparticles 88 nm lowest entrapment efﬁciency 691 Formulation F 14 highest concentration PLGA 10 mgml acetone exhibited highest drug entrapment efﬁciency 908 cost comparatively larger nanoparticles 158 nm This increase size nanoparticles increment PLGA concentration acetone increased viscosity reduced diffusion PLGA form acetone antisolvent Ansari 2017 324 Effect drug polymer nanoparticles The effect drug particle size size distribution zeta potential investigated preparing formulations drug polymer Fig 5 The nanoparticles drug formulation F14 prepared nanoprecipitation organic solu tion baricitinib resulted large nanoparticles 427 nm high PDI 046 low zeta potential cid186 mV Similarly nanoparticles polymer formulation F15 prepared nanoprecipitation organic solution PLGA resulted larger nanoparticles 635 nm higher PDI 086 lower zeta potential cid155 mV The larger size nanoparticles high PDI low zeta potential indicative particle growth aggregation absence polymer Polymeric materials present organic phase formulation F1F13 prevent aggregation nanosuspension forming layer nanoprecipitates formed control stabilize size particles The mechanism stabilization size nanopar ticles include steric stabilization electrostatic Fig 2 Effect solvent size poly dispersity index PDI zeta potential entrapment efﬁciency baricitinib encapsulated PLGA nanoparticles AC acetone AN acetonitrile DCM dichloromethane EA ethyl acetate THF tertahydrofuron 496 MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 Fig 3 Effect solvent antisolvent ratio size poly dispersity index PDI zeta potential entrapment efﬁciency baricitinib encapsulated PLGA nanoparticles Fig 4 Effect PLGA concentration size poly dispersity index PDI zeta potential entrapment efﬁciency baricitinib encapsulated PLGA nanoparticles repulsion presence surface charges combination The drug suspension F16 exhibited poorer particle characteristics average particle size 935 nm highest PDI 096 lowest zeta potential value cid111 mV Based combined effect types solvent solvent anti solvent ratio phase ratio PLGA concentration drug polymer ratio desired properties nanoparticles low est size lowest PDI highest zeta potential high entrap ment efﬁciency formulation F8 selected optimized formulation evaluations The smaller nanoparticles known absorbed taken mucosal cells better larger counterparts Win Feng 2005 The particle size PDI zeta potential nanoparticles evaluated zeta sizer nano ZS Malvern UK An image size analysis zeta potential analysis F8 presented Fig 6 Fig 7 respectively The characterization nanoparticle suspension term zeta potential important tool prediction stability dispersions It considered index repulsion value zeta potential stability nano suspension A higher zeta potential means higher electric charge surface NPs prevents aggregation nanopar ticles In present investigation average zeta potential cid1105 mV prepared formulation value cid1125 56 mV optimized F8 It reported absolute Zeta potential values 30 mV provide good stability Jiang et al 2009 However large molecular weight solids polymers known stabilize suspensions steric hindrance despite low zeta potential Honary Zahir 2013 33 Characterization nanoparticles The characterization optimized nanoparticle formulation F 8 carried studying size surface morphology SEM powder properties XRD FTIR DSC drug release study release mechanism 331 Size surface characterization The size surface nanoparticles characterized Scanning Electron Microscopy Zeiss EVO LS10 Cambridge UK The SEM photographs baricitinib encapsulated PLGA nanoparti cles F8 shown Fig 8 The size nanoparticles MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 497 Fig 5 Effect drug polymer size poly dispersity index PDI zeta potential entrapment efﬁciency baricitinib encapsulated PLGA nanoparticles Fig 6 Nanoparticle size analysis formulation F8 obtained Malvern zatasizer nano ZS nanometer range shape nanoparticles spherical The sizes obtained SEM image consis tent obtained dynamic light scattering studies zetasizer nano Malvern UK The larger particles observed photomicrograph particle growth freeze drying sample preparation imaging studies involved dispersion dried particles deionized water 332 Xray diffraction study baricitinib encapsulated nanoparticles The Xray diffraction study pure baricitinib baricitinib encapsulated nanoparticles performed investigate particle nature baricitinib encapsulation The XRD spec tra pure baricitinib baricitinib encapsulated nanoparticles presented Fig 9 The spectrum pure baricitinib exhibited characteristics sharp peaks 125 425cid3 high intensity 200 counts reaching upto 1600 counts These peaks indicative crystalline nature baricitinib Fig 9a However spectrum PLGA Fig 9b exhibited peaks indicative noncrystalline nature polymer It reported PLGA composed L isomers polylactic acid polyglycolic acid crystalline composed racemic mixtures levo dextro rotatory forms amorphous nature Furthermore PLGA copolymers composed 70 glycolic acid known amorphous Dinarvand et al 2011 In present study D LPLGA 5050 exhibited amorphous nature Xray diffraction 498 MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 Fig 7 Nanoparticle zetapotential analysis formulation F 8 obtained Malvern zatasizer nano ZS baricitinib Fig 10b exhibited sharp characteristic endotherm melting point peak 2153 cid3C However thermogram barici tinib encapsulated nanoparticles Fig 10a exhibited short endotherm 553 cid3C correspond glass transition temperature Tg polymer PLGA The absence sharp characteristic endothermic peak baricitinib indicated encap sulation drug polymer Furthermore drug molecularly dispersed amorphous mixture poly mer The melting point rage baricitinib reported literature 212 215 cid3C European Patent Application 2018 Baricitinib API STANDARDS 2018 The melting point observed study 2153 cid3C close reported values Likewise glass transition temperature polymer PLGA 5050 observed 553 cid3C close reported values 4555 cid3C literature Pyo Park Jonnalagadda 2006 334 Fourier transform infrared spectroscopy PLGA nanoparticles FTIR spectroscopy pure baricitinib PLGA nanoparticles encapsulated baricitinib performed ﬁnd chem ical molecular interaction baricitinib PLGA polymer The FTIR spectra baricitinib baricitinib encapsu lated PLGA nanoparticles presented Fig 10 The FTIR spec trum baricitinib Fig 11a exhibited strong absorption bands wavenumbers 320318 311737 284738 225631 185743 157941 cmcid11 corresponding NAH stretching CAH stretching aromatic ACAH stretching methyl methylene groups CN stretching CN stretching CC aro matic stretching respectively The spectrum baricitinib encap sulated nanoparticles exhibited characteristic absorption bands observed spec trum baricitinib Fig 11a weak absorption bands 288981 176069 cmcid11 assigned ACAH stretching CO stretching methyl carbonyl groups present PLGA polymer Erbetta et al 2012 The absence characteristic absorption bands baricitinib spectrum PLGA nanoparticles indicates physical entrapment baricitinib nanoparticles Fig 11b Fig 8 Scanning Electron photomicrograph baricitinib encapsulated PLGA nanoparticles formulation F8 Magniﬁcation1390cid4 EHT electron high tension 5 kV WD working distance 8 mm study Fig 9b showing consistency available literatures You et al 2005 Dinarvand et al 2011 The XRD spectrum baricitinib encapsulated PLGA nanoparticles Fig 9c exhibited noncrystalline behaviour amorphous nature intense peak 2 broad diffused peaks low intensity approximately 385 393 counts 193 232 degree respectively This behaviour amorphization crys talline baricitinib nanoencapsulation PLGA poly mer causing loss high intensity peaks crystalline baricitinib observed Fig 9a 333 Differential Scanning calorimetry nanoparticles Differential Scanning calorimetry pure baricitinib barici tinib encapsulated nanoparticles performed compare characteristics baricitinib nanoencapsulation The DSC thermograms baricitinib baricitinib encapsulated nanoparticles presented Fig 10 These DSC thermogram MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 499 Fig 9 Xray diffractogram baricitinib b PLGA c baricitinib encapsulated PLGA nanoparticles Fig 10 Differential Scanning calorimetry thermogram baricitinib encapsulated PLGA nanoparticles b baricitinib 335 In vitro release study baricitinib encapsulated PLGA nanoparticles The vitro release studies baricitinib baricitinib encap sulated PLGA nanoparticles conducted phosphate buffer pH 68 05 wv sodium lauryl sulphate maintain sink condition mimic vivo environment The vitro release proﬁles pure baricitinib baricitinib encapsulated PLGA nanoparticles F8 shown Fig 12 The PLGA nanopar ticles exhibited biphasic release pattern initial burst release baricitinib 38 2 h followed slow release drug period 24 h 93 The burst release baricitinib nanoparticles adsorbed drug surface PLGA polymer The drug release sustained release phase result slow degradation PLGA dissolution media The vitro release data ﬁtted kinetic models understand mechanism release baricitinib PLGA nanoparticles The drug release proﬁle baricitinib encapsulated 500 MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 Fig 11 FTIR Spectra baricitinib b baricitinib encapsulated PLGA nanoparticles b n t c r b f o e s e l e R 100 90 80 70 60 50 40 30 20 10 0 BARICITINIB F8 0 4 8 12 Time h 16 20 24 Fig 12 In vitro release proﬁles baricitinib N baricitinib encapsulated PLGA nanoparticles formulation F8 j phosphate buffer pH 68 05 wv sodium lauryl sulphate Table 5 Kinetic models kinetic release rate constants correlation coefﬁcients vitro release proﬁle baricitinib encapsulated PLGA nanoparticles Kinetic models ﬁtted Correlation coefﬁcients R2 Release rate constants Zero order First order HixsonCrowell Higuchi Korsmeyer Peppas 0708 0911 0854 0918 0563 1409 0279 0627 0549 0026 nanoparticles best ﬁtted Higuchi model regression coefﬁcient R2 highest 0918 Higuchi model kinetic models tested release pro ﬁle Table 5 4 Conclusions The baricitinib encapsulated PLGA nanoparticles produced nanoprecipitation method small size low PDI good entrapment efﬁciency In vitro release proﬁle exhibited sustained release behaviour resulting 89 release 12h period 93 24h period PLGA polymer pronounced effect sustaining drug release enhancing sol ubility drug encapsulated This sustained release behavior utilized management chronic rheumatoid arthri tis helpful reduction effects minimizing dose baricitinib We plan conduct efﬁcacy study bioavailability studies animals near future Acknowledgments The authors acknowledge support given Mr Khalid Al huwaisahl graduate pharmacy student Dr Mohammad Afroz Bakht Imtiyaz Ali Xray Diffraction spectra Dr Faiyaz Shakeel Scanning electron microscopy imaging Funding This project funded deanship scientiﬁc research Prince Sattam bin Abdulaziz University Saudi Arabia funding number2017037329 Conﬂicts The authors declare conﬂict The funders role design study collection analyses inter pretation data writing manuscript deci sion publish results References classiﬁcation criteria Aletaha D Neogi T Silman AJ Funovits J Felson DT Bingham III CO Birnbaum NS Burmester GR Bykerk VP Cohen MD Combe B 2010 2010 rheumatoid arthritis RheumatologyEuropean League Against Rheumatism collaborative initiative Arthritis Rheumatol 62 9 25692581 httpsdoiorg101002art27584 Alshehri S Shakeel F Ibrahim M Elzayat E Altamimi M Shazly G Mohsin K Alkholief M Alsulays B Alshetaili A Alshahrani A Almalki B Alanazi F 2017 Inﬂuence microwave technology solid dispersions mefenamic acid ﬂufenamic acid PLoS One 12 7 e0182011 httpsdoiorg101371 journalpone0182011 American College MJ Ansari SM Alshahrani Saudi Pharmaceutical Journal 27 2019 491501 501 Ansari MJ 2016 Preparation evaluation dicomponent tricomponent molecular inclusion complexes silymarin Lat Am J Pharm 35 604608 httplatamjpharmorgprevious_issuephpvol35num3 Huang W Zhang C 2018 Tuning size poly lacticcoglycolic acid PLGA nanoparticles fabricated nanoprecipitation Biotechnol J 13 1 1700203 1700211 httpsdoiorg101002biot201700203 Ansari MJ 2017 Factors affecting preparation properties nanoparticles nanoprecipitation method Indo Am J Pharm Sci 4 12 48544858 https doiorg105281zenodo1134425 Assessment report Olumiant Available online httpswwwemaeuropa eudocumentsassessmentreportolumianteparpublicassessmentreport_ enpdf accessed 10242018 Baricitinib API standards Available online httpswwwclearsynthcomen CST48553html accessed 10272018 Baricitinib technical information Available online httpswwwscbtcomscbt productbaricitinib1187594097 accessed 10242018 Costabile G Gasteyer KI Nadithe V Van Denburgh K Lin Q Sharma S Reineke JJ Firestine SM Merkel OM 2018 Physicochemical vitro evaluation drug delivery antibacterial synthetic benzophenone biodegradable PLGA nanoparticles AAPS PharmSciTech httpsdoiorg 101208s1224901811879 Sep 25 Dahan A Miller JM 2012 The solubilitypermeability interplay implications formulation design development poorly soluble drugs AAPS J 14 2 244251 httpsdoiorg101208s1224801293376 Dinarvand R Sepehri N Manoochehri S Rouhani H Atyabi F 2011 Polylactidecoglycolide nanoparticles controlled delivery anticancer agents Int J Nanomed 6 877895 httpsdoiorg102147IJNS18905 Drug Approval Package Olumiant baricitinib Available online httpswww accessdatafdagovdrugsatfda_docsnda2018207924Orig1s000TOCcfm accessed 10242018 Drugbank identiﬁcation baricitinib 2018 Available online https wwwdrugbankcadrugsDB11817 accessed 10242018 Erbetta CDAC Alves RJ Resende JM Souza Freitas RF Sousa RG 2012 Synthesis characterization poly D Llactidecoglycolide copolymer J Biomater Nanobiotechnol httpsdoiorg104236 jbnb201232027 208225 02 3 European Patent Application Available online httpsdataepoorgpublication serverrestv10publicationdates20180117patents EP3269719NWA1documentpdf accessed 10272018 Fessi H Puisieux F Devissaguet JP Ammoury N Benita S 1989 Nanocapsule formation interfacial polymer deposition following solvent displacement Int J Pharm 55 1 R1R4 httpsdoiorg1010160378517389902810 Finsy R De Jaeger N 1991 Particle sizing photon correlation spectroscopy Part II Average values Part Part Syst Charact 8 14 187193 httpsdoiorg 101002ppsc19910080135 Jiang J Oberdörster G Biswas P 2009 Characterization size surface charge agglomeration state nanoparticle dispersions toxicological studies J Nanopart Res 11 1 7789 httpsdoiorg101007s1105100894464 Joshi G Kumar A Sawant K 2016 Bioavailability enhancement Caco2 cells uptake intestinal transport orally administered lopinavirloaded PLGA nanoparticles Drug Del 23 9 34923504 httpsdoiorg101080 1071754420161199605 Makadia HK Siegel SJ 2011 Poly lacticcoglycolic acid PLGA biodegradable controlled drug delivery carrier Polymers 3 3 13771397 httpsdoiorg 103390polym3031377 Mu L Feng SS 2003 A novel controlled release formulation anticancer drug paclitaxel Taxolcid4 PLGA nanoparticles containing vitamin E TPGS J Controlled Release 86 1 3348 httpsdoiorg101016S0168365902 003206 Product information baricitinib Available online httpswwwcaymanchemcom pdfs16707pdf accessed 10242018 Pyo Park PI Jonnalagadda S 2006 Predictors glass transition J Appl biodegradable polylactide polylactidecoglycolide polymers Polym Sci 100 3 19831987 httpsdoiorg101002app22135 Raﬁei P Haddadi A 2017 Pharmacokinetic consequences PLGA nanoparticles docetaxel drug delivery Pharm Nanotechnol 5 1 323 httpsdoiorg 1021742211738505666161230110108 Sahu BP Das MK 2014 Nanosuspension enhancement oral bioavailability felodipine App Nanosci 4 2 189197 httpsdoiorg101007s13204 01201883 Shen J Burgess DJ 2013 In vitro dissolution testing strategies nanoparticulate drug delivery systems recent developments challenges Drug Del Transl Res 3 5 409415 httpsdoiorg101007s133460130129z Singh G Pai RS 2014 Optimized PLGA nanoparticle platform orally dosed transresveratrol enhanced bioavailability potential Expert Opin Drug Deliv 11 5 647659 httpsdoiorg101517174252472014890588 Venkatesh DN Baskaran M Karri VVSR Mannemala SS Radhakrishna K Goti S 2015 Fabrication vivo evaluation Nelﬁnavir loaded PLGA nanoparticles enhancing oral bioavailability therapeutic effect Saudi Pharm J 23 6 667674 httpsdoiorg101016jjsps201502021 Win KY Feng SS 2005 Effects particle size surface coating cellular uptake polymeric nanoparticles oral delivery anticancer drugs httpsdoiorg101016j Biomaterials biomaterials200407050 27132722 15 26 Honary S Zahir F 2013 Effect zeta potential properties nanodrug delivery systemsa review Part 2 Trop J Pharm Res 12 2 265273 https doiorg104314tjprv12i219 You Y Min BM Lee SJ Lee TS Park WH 2005 In vitro degradation behavior electrospun polyglycolide polylactide poly lactidecoglycolide J Appl Polym Sci 95 2 193200 httpsdoiorg101002app21116